Pharma BD Deal Intelligence
Pfizer and BioNTech entered a co-development and co-commercialization agreement for BioNTech's mRNA COVID-19 vaccine candidates (BNT162 program). Pfizer paid $185M upfront ($72M cash + $113M equity investment) with up to $563M in milestone payments. Development costs were split 50/50, with Pfizer initially funding 100% and BioNTech repaying its share from commercialization. The resulting Comirnaty vaccine generated over $36B in 2021 revenue alone and remains the most commercially successful product of the alliance. Revenue has since normalized sharply from its pandemic peak: Pfizer's FY2025 total revenue was $62.6B (down 2% YoY), with declining COVID-19 product sales the primary driver as US vaccine recommendations narrowed. The franchise also carries a patent-liability overhang: a Dusseldorf court ruled in March 2025 that Pfizer/BioNTech infringed Moderna's mRNA patents and must account for Comirnaty profits and pay compensation (subject to appeal), with parallel US litigation ongoing.